CLOs on the Move

Dentalcorp

www.dentalcorp.ca

 
dentalcorp is Canada`s largest network of dental practices, committed to advancing the overall well-being of Canadians by aiming to deliver the best clinical outcomes and unforgettable experiences. dentalcorp acquires leading dental practices, uniting them in a common goal: to be Canada`s most trusted healthcare network. Leveraging its industry-leading technology, know-how and scale, dentalcorp offers professionals the unique opportunity to retain their clinical autonomy while unlocking their potential for future growth. dentalcorp provides world-class resources to Partners including Talent & Recruitment, Human Resources, Training & Development, Legal & Compliance, Practice Optimization, Marketing, IT, Procurement, Finance, AP, and Payroll. We enable the ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.dentalcorp.ca
  • 181 Bay Street Suite 2600
    Toronto, ON CAN M5J 2T3
  • Phone: 416.558.8338

Executives

Name Title Contact Details
Julian Perez
Chief Legal Officer Profile

Similar Companies

Definitive Healthcare

Definitive Healthcare is the leading provider of data and intelligence on hospitals, physicians and other healthcare providers. Definitive Healthcare`s data provides clients with the analytics and insight needed to effectively segment and research the healthcare provider market.

Amsino International

Amsino International is a Pomona, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Intelligent Medical Systems

Intelligent Medical Systems, Inc. is a Alpine, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.

The Elizabeth Center for Cancer Detection

The Elizabeth Center for Cancer Detection is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.